Kyverna: KYV-101 demonstrates ‘promising’ outcomes across multiple indications

On June 14, Kyverna Therapeutics hosted an industry symposium at EULAR in Vienna with a data update on KYV-101, its lead CAR T-cell therapy candidate. In the data presentation, Kyverna said early KYV-101 data demonstrate “promising” outcomes across multiple indications. In the KYV-101 CAR safety and efficacy experience from hematology, the company said CAR demonstrated an improved safety profile in a 20-patient study without compromising efficacy and that data supported dose-selection for the autoimmune disease setting. In myasthenia gravis, within 60 days of infusion, improved symptoms and mobility were observed, Kyverna says.